Post-HCT outcomes combined and by cohort (unmanipulated vs CD34+-selected)
| . | 1-year OS (IQR), % . | 3-year OS (IQR), % . | 1-year NRM (IQR), % . | 3-year NRM (IQR), % . | CI G2-4 aGVHD, day 100 (IQR), % . | CI G2-4 aGVHD, day 365 (IQR), % . |
|---|---|---|---|---|---|---|
| Total | 80 (76-83) | 63 (59-67) | 13 (10-16) | 22 (18-26) | 19 (16-23) | 33 (29-37) |
| Cohort 1 (unmodified) | 84 (78-90) | 68 (60-75) | 8 (4-12) | 16 (10-23) | 23 (16-30) | 41 (33-49) |
| Cohort 2 (CD34) | 78 (74-83) | 61 (56-67) | 15 (12-19) | 25 (20-29) | 18 (14-22) | 30 (25-34) |
| . | 1-year OS (IQR), % . | 3-year OS (IQR), % . | 1-year NRM (IQR), % . | 3-year NRM (IQR), % . | CI G2-4 aGVHD, day 100 (IQR), % . | CI G2-4 aGVHD, day 365 (IQR), % . |
|---|---|---|---|---|---|---|
| Total | 80 (76-83) | 63 (59-67) | 13 (10-16) | 22 (18-26) | 19 (16-23) | 33 (29-37) |
| Cohort 1 (unmodified) | 84 (78-90) | 68 (60-75) | 8 (4-12) | 16 (10-23) | 23 (16-30) | 41 (33-49) |
| Cohort 2 (CD34) | 78 (74-83) | 61 (56-67) | 15 (12-19) | 25 (20-29) | 18 (14-22) | 30 (25-34) |
aGVHD, acute graft-versus-host disease; NRM, nonrelapse mortality; OS, overall survival; CI, cumulative incidence.